Tariffs turmoil is giving pill-maker a headache

PHARMACEUTICAL firm Shield Therapeutics has admitted that US tariffs spell risks and uncertainties for its business.

- TOM KEIGHLEY Business Reporter [e-mail]

The maker of iron deficiency-fighting tablets, which has operations in the North East and the US, told investors the change in American economic policy could lead to increased costs, supply chain disruptions and margin pressure.

And bosses said the potential for future tariffs and retaliatory action has created a climate of unpredictability that could impact its planning and financial performance.

Shield is in the midst of a major push to grow sales of its Accrufer tablets in the huge US market, where it says it has achieved strong market results working with partner Viatris. In full year 2024 results, the commercial stage firm said it had grown Accrufer prescriptions to about 150,000, almost double 2023 levels.